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IntroductIon
Maternal obesity influences a number of metabolic and physio­
logical factors that can affect the course of pregnancy (1–3). 
Many of the effects of obesity may be associated with metabolic 
dysregulation characterized by adipose tissue dysfunction and 
disruption of the normal feedback systems that maintain meta­
bolic homeostasis (4–6). Pregnancy is itself a unique metabolic 
state associated with a complex set of physiological changes 
that optimize energy reserve for the mother and substrate pro­
vision for the fetus (7). There are few descriptions of how the 
metabolic dysregulation associated with obesity may influence 
the physiological changes of pregnancy. As one example, it has 
recently been shown that insulin may have different metabolic 
effects in obese compared to nonobese pregnant women (8).
Metabolic changes that arise from adipocyte and adipose 
tissue dysfunction in obesity influence a number of physio­
logical factors (5) that may affect the course of pregnancy. 
Among these factors, leptin plays a particularly important 
role in the regulation of maternal energy metabolism during 
pregnancy (9–11). Serum leptin levels are generally thought 
to be related to adipose tissue mass and are correlated with 
body fat mass and BMI in both nonpregnant (12) and 
pregnant adults (13). However, the regulation of mater­
nal leptin during pregnancy is complex (11). Serum leptin 
concentrations nearly doubled during the course of a nor­
mal pregnancy (13–15), though factors other than fat mass 
alone, such as placental production, are responsible for this 
increase (11,16,17). Such changes are thought to be involved 
in optimizing the availability of substrates necessary for fetal 
growth, particularly by mobilizing maternal fat stores (11). 
Metabolic disturbances arising from adipocyte and adipose 
tissue dysfunction in obese women may alter the regula­
tion of leptin during pregnancy. However, prior studies have 
not adequately documented how the longitudinal trends in 
maternal plasma leptin levels during pregnancy may differ in 
obese women compared to nonobese women.
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Maternal obesity influences a number of metabolic factors that can affect the course of pregnancy. Among these 
factors, leptin plays an important role in energy metabolism and fetal development during pregnancy. Our objective 
was to estimate the influence of maternal overweight/obesity on variation in the maternal serum leptin profile 
during pregnancy. In a prospective cohort of 143 adult gravidas with singleton pregnancies presenting for general 
prenatal care, we measured serum leptin levels at 6–10, 10–14, 16–20, 22–26, and 32–36 weeks’ gestation. The 
longitudinal effects of maternal prepregnancy BMI, categorized as nonoverweight (≤26.0 kg/m2) and overweight/obese 
(>26.0 kg/ m2), on serum leptin concentration were analyzed using linear mixed models. Overweight/obese women 
had significantly higher serum leptin concentrations than their nonoverweight counterparts throughout pregnancy 
(P < 0.01). Although these concentrations increased significantly across gestation for both groups, the rate of increase 
was significantly smaller for overweight/obese women (P < 0.05). To investigate whether these differences merely 
reflected differences in weight-gain patterns between the two groups, we examined an index of leptin concentration 
per unit body weight (leptin (ng/ml)/weight (kg)). Overweight/obese women had a significantly higher index throughout 
pregnancy (P < 0.01). However, although this index increased significantly across pregnancy for nonoverweight 
women, it actually decreased significantly for overweight/obese women (P < 0.01). Our results suggest that factors 
other than fat mass alone influence leptin concentrations in overweight/obese women compared to normal-weight 
women during pregnancy. Such factors may contribute to differences in the intrauterine environment and its influence 
on pregnancy outcomes in the two groups.
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Our goal was to characterize longitudinal trends in  maternal 
serum leptin levels during pregnancy in overweight and obese 
women, compared to their nonoverweight counterparts. 
We specifically examined the relationship of maternal pre­
pregnancy BMI with gestational age­ and maternal weight– 
dependent changes in leptin levels in pregnant women enrolled 
in a prospective cohort study. These analyses are a preliminary 
step toward defining how the metabolic dysregulation asso­




Data were collected as part of a prospective cohort study of pregnant 
women who presented for prenatal care in early first trimester to the 
University of Michigan Health System. The Institutional Review Board 
of the University of Michigan Medical School approved the study pro­
tocols. At the time of enrollment, participants were 18–45 years of 
age, between 6 and 10 weeks’ gestation with a singleton pregnancy, 
and intended to deliver at the study hospital. Informed consent was 
obtained at the initial visit. Participants were seen at four additional 
study visits at 10–14, 16–20, 22–26, and 32–36 weeks’ gestation. 
Pregnancies complicated by major structural fetal abnormalities or 
prenatally diagnosed aneuploidy were excluded from the analysis. We 
analyzed data obtained at each visit from a brief interview, maternal 
anthropometric measurements, and fetal ultrasound measurements. 
Less than 1% of data were missing for any variable. Data analyses were 
carried out on a cohort of 143 women who delivered a live infant and 
were measured for all relevant variables.
data collection and study variables
Baseline maternal characteristics were collected by questionnaire upon 
entry into the study as well as subsequent review of medical records. 
These data included age and self­report of race and ethnicity, years of 
education completed, income, marital status, date of last menstrual 
period, prior and current pregnancy histories, maternal chronic illness, 
medications, alcohol use, and exposure to tobacco smoke. Standing 
height was measured at the baseline visit using a wall­mounted sta­
diometer. Weight was measured in light street clothes, without shoes, 
on a calibrated electronic scale (Scale­Tronix, White Plains, NY). 
Maternal prepregnancy weight was collected by self­report at the base­
line visit. Prepregnancy BMI was calculated using height and prepreg­
nancy weight (BMI = weight/height2), and categorized into two levels 
using the Institute for Medicine’s classification (18) as nonoverweight 
(≤26.0 kg/ m2) and overweight/obese (>26.0 kg/m2).
Gestational age was estimated from participant’s recall of the first day 
of the last menstrual period prior to 8 weeks’ gestation and corrobo­
rated by three independent ultrasonographic measurements of crown­
rump length between 6 and 10 weeks’ gestation. If the discrepancy with 
dates was >6 days, the ultrasound estimate of gestational age was used. 
Although early first­trimester ultrasound­based dating is generally 
thought to be highly accurate (19), it may be systematically biased in 
overweight and obese gravidas (20,21). As such, our approach was meant 
to provide a best estimate of the gestational age using ultrasound data to 
reduce potential errors in participant reporting of the first day of the last 
menstrual period (22).
At each visit, maternal serum was collected using a standard serum 
separator tube (BD, Franklin Lakes, NJ), aliquoted, and stored at −80 °C 
for analysis. Serum leptin concentration was measured using a standard 
commercial radioimmunoassay kit (Linco Research, St Charles, MO). 
This kit is a double­antibody radioimmunoassay using an 125I­human 
 leptin tracer, a rabbit antihuman leptin serum as the first antibody, and 
a goat anti­rabbit gamma globulin–polyethylene glycol complex as 
the  second antibody. A purified recombinant human leptin is used as 
 standard. The limit of sensitivity for the assay is 0.5 ng/ml. The interassay 
coefficient of variation is 6.4% at 3.5 ng/ml and 6.0% at 23.5 ng/ml. These 
assays were performed in the Chemistry Laboratory of the Michigan 
Diabetes Research and Training Center.
statistical analysis
All statistical analyses were performed using SAS version 9.1 (SAS 
Institute, Cary, NC).
Univariate analyses were used to describe the demographic character­
istics of the study sample.
The Fisher exact test was used to assess statistical significance of 
 categorical variables; the Student’s t­test was used for continuous vari­
ables. A P value of <0.05 was considered statistically significant.
Our analysis includes repeated leptin measurements over the course 
of pregnancy. To account for the correlations between repeated meas­
ures of leptin over gestation, we used a mixed linear regression model as 
implemented in the MIXED module in SAS (23). Unlike conventional 
linear regression models, mixed linear regression models allow the data 
to exhibit correlation and nonconstant variability by including both fixed 
effect and covariance parameters. It is possible to model the covariance 
structure of the repeated measurements to increase efficiency so that the 
estimates and standard errors can be efficiently generated. In addition, 
the mixed linear modeling procedure used here implements a likelihood­
based estimation method so that all available data are used in the analysis 
without excluding subjects with missing data. For these analyses, repeated 
measures of leptin across pregnancy were analyzed using a model in 
which BMI stratum was a fixed factor that varied between subjects; ges­
tational age at each leptin measurement was a repeated factor that varied 
within subjects; and an interaction term between BMI stratum and time 
(gestational age) was included to estimate differences in the rate of change 
of the measurements over the course of gestation for both BMI groups.
results
Table 1 presents the sociodemographic and health charac­
teristics of the 143 participants in our sample. Our sample is 
quite homogeneous with regard to measures of socio economic 
status and race. However, as shown in Figure 1, there was 
considerable variation in prepregnancy BMI. As shown in 
Table 1, there were significant differences in the characteristics 
of women with nonoverweight BMIs compared to those with 
overweight/obese BMIs. Figure 2 presents the maternal weight 
and weight­gain characteristics of our sample. As expected, we 
found that the maternal weight measured at each study visit 
increased steadily from 6 to 36 weeks’ gestation. However, 
the rate at which the maternal weight increased across gesta­
tion was significantly lower for women with overweight/obese 
prepregnancy BMIs compared to women with nonoverweight 
BMIs (P < 0.05).
We then analyzed the relationship between maternal serum 
leptin and gestational age in nonoverweight and overweight/
obese women. Figure 3 contains plots of leptin levels over the 
course of pregnancy, stratified on maternal prepregnancy BMI. 
Starting in early pregnancy, we found that leptin concentration 
significantly increased with advancing gestation in both strata. 
Women with overweight/obese BMIs had significantly higher 
serum leptin concentrations than their nonoverweight coun­
terparts. However, the rate at which leptin levels increased 
across gestation was significantly lower for women with over­
weight/obese BMIs (P < 0.01).
To investigate whether differences in the leptin profile 
merely reflected differences in weight and gestational weight 
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gain between the two groups, we subsequently examined an 
index of leptin concentration per unit body weight (leptin 
(ng/ml)/weight (kg)). Figure 4 contains plots of this index 
across pregnancy. Women with overweight/obese BMIs had 
significantly higher serum leptin per unit body weight than 
their nonoverweight counterparts throughout pregnancy (P < 
0.01); in early first trimester, the value of this index was 0.24 ng/
ml/ kg for nonoverweight weight women and 0.42 ng/ ml/kg for 
overweight/obese women. Notably, although the leptin per 
body weight index increased significantly across pregnancy 
for nonoverweight women, it actually decreased significantly 
for overweight/obese women (Figure 4); by third trimester, 
the index had increased to nearly 0.30 ng/ml/kg in nonover­
weight women, but had decreased to about 0.37 ng/ml/kg in 
overweight/obese women. As a result, although the average 
 circulating leptin concentration per kilogram of body mass 











BMI >26.0  
kg/m2**  
N (%)
Sample size 143 85 (59.4) 58 (40.6)
Race*
 White 115 (80.4) 72 (84.7) 43 (74.1)
  African-
American
11 (7.7) 3 (3.5) 8 (13.8)
 Asian 7 (4.9) 6 (7.1) 1 (1.7)
 Other 10 (7.0) 4 (4.7) 6 (10.3)
Ethnicity*
 Non-Hispanic 137 (95.8) 84 (98.8) 53 (91.4)
 Hispanic 6 (4.2) 1 (1.2) 5 (8.6)
Maternal age**
 ≤30 79 (55.2) 39 (45.9) 40 (69.0)
 >30 64 (44.8) 46 (54.1) 18 (31.0)
Parity
 Nulliparous 54 (37.8) 33 (38.8) 21 (36.2)
 Multiparous 89 (62.2) 52 (61.2) 37 (63.8)
Marital status
 Married 118 (82.5) 74 (87.1) 44 (75.9)
 Not married 25 (17.5) 11 (12.9) 14 (24.1)
Highest educational level completed**
 College or less 85 (59.4) 41 (48.2) 44 (75.9)
 Post graduate 58 (40.6) 44 (51.8) 14 (24.1)
Income**
  ≤$80,000 per 
year
72 (50.3) 33 (38.8) 39 (67.3)
  >$80,000 per 
year
70 (49.0) 52 (61.2) 18 (31.0)
 Missing 1 (0.7) 0 (—) 1 (1.7)
Insurance
  Private 
insurance
125 (87.4) 77 (90.6) 48 (82.8)
  Medicaid/
Medicare
18 (12.6) 8 (9.4) 10 (17.2)
Smoking
  Not during 
pregnancy
132 (92.3) 78 (91.8) 54 (93.1)
  During 
pregnancy
11 (7.7) 7 (8.2) 4 (6.9)
*P < 0.05; statistical significance of difference between low and high BMI groups. 
**P < 0.01; statistical significance of difference between low and high BMI groups.
0
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Figure 1 The distribution of maternal prepregnancy BMI for our sample. 
The BMI values for nonoverweight women (≤26.0 kg/m2) are shown in 
black and the values for overweight/obese women (>26.0 kg/m2) are 
shown in gray.
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Figure 2 The relationship of maternal weight (kg) to gestational 
age for women with nonoverweight prepregnancy BMI (β = 0.530 kg/
week, 95% confidence interval (CI): 0.545, 0.515) and overweight/
obese prepregnancy BMI (β = 0.424, 95% CI: 0.454, 0.394). Data for 
nonoverweight prepregnancy BMI are shown in black; and overweight/
obese prepregnancy BMI are shown in gray.
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was 1.8 times higher in obese/overweight women at the begin­
ning of pregnancy, it was only 1.2 times higher at the end of 
pregnancy (P < 0.01).
dIscussIon
This work is the first to clearly demonstrate that overweight/
obese (prepregnancy BMI >26.0 kg/m2) women have quali­
tatively different leptin profiles across pregnancy than non­
overweight (prepregnancy BMIs ≤26.0 kg/m2) women. Serum 
leptin concentrations are closely correlated with the  percentage 
of body fat in both nonpregnant (12) and pregnant adults (13). 
Accordingly, we found that maternal serum leptin concentra­
tions were proportional to maternal body mass and weight 
gain from the start of pregnancy. In addition, consistent with 
several prior studies on smaller cohorts of women (13–15), 
we observed that maternal serum leptin concentration sig­
nificantly increased with advancing gestation in both strata. 
At every time point, women with overweight/obese prepreg­
nancy BMIs had significantly higher serum leptin concentra­
tions than their nonoverweight counterparts. However, we 
observed that the rate at which leptin levels increased across 
gestation was significantly lower for overweight/obese women, 
in part, due to their lower weight gain. These differences are 
conventionally attributed to differences in the weight­gain 
characteristics of the two groups, particularly because studies 
of body composition during pregnancy suggest that the gain 
in fat mass per unit body weight is less for overweight/obese 
compared to nonoverweight women (24).
However, the differences we observe in the index of leptin to 
body weight (Figure 4) suggest that factors other than fat mass 
alone must contribute due the differences in leptin concentra­
tions between the two groups. In nonpregnant women, leptin 
release per gram of adipose tissue is approximately two times 
greater in obese than in lean subjects (25). This is consistent with 
the differences we observe in the index of leptin to body weight 
at the beginning of pregnancy (Figure 3). However, although 
the index of leptin to body weight increased significantly for 
nonoverweight women, it actually decreased significantly in 
overweight/obese women. In other words, overweight/obese 
gravidas do not show the progressive increases in leptin pro­
duction per unit of body mass that are seen in nonoverweight 
women. As a result, the average circulating leptin concentra­
tion per kilogram of body mass was only 1.2 times higher for 
overweight/obese than nonoverweight women at the end of 
pregnancy.
The observed differences in the leptin/body weight index 
suggest that the factors regulating leptin levels during preg­
nancy differ between overweight/obese and normal­weight 
women. For example, our findings may reflect a lower produc­
tion of leptin per unit mass of adipose or placental tissue in 
overweight/obese women as pregnancy progresses. Such dif­
ferences may be due to progressively lower adipocyte ob gene 
expression in these tissues. Variation in ob gene expression in 
adipocytes is an important cellular mechanism responsible 
for regulating circulating leptin levels in nonpregnant obese 
women (25). In pregnant women, differences in leptin produc­
tion in nonadipose tissue, such as the placenta (11,17), may 
also contribute to our findings. Our study was not designed to 
differentiate between these mechanisms.
Differences in gene expression may be a consequence of 
more general metabolic diferences between the two groups. 
For example, both plasma insulin and glucocorticoids are 
associated with expression of leptin mRNA and the leptin 
secretion rate (26). However, in obese individuals, prolonged 
exposure to the combination of insulin and dexamethasone 
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Figure 3 The relationship of maternal serum concentrations of leptin 
(ng/ml) to gestational age (days) for women with nonoverweight 
prepregnancy BMI (β = 0.038, 95% confidence interval (CI): 0.044, 
0.032) and overweight/obese prepregnancy BMI (β = 0.007, 95% CI: 
0.015, −0.001). Data for nonoverweight prepregnancy BMI are shown in 
black; and overweight/obese prepregnancy BMI are shown in gray.
0.0





























Figure 4 The relationship of maternal serum concentrations of leptin 
per unit body weight (ng/ml/kg) to gestational age (days) for women with 
nonoverweight prepregnancy BMI (β = 0.00025, 95% confidence interval 
(CI): 0.00034, 0.00017) and overweight/obese prepregnancy BMI 
(β = −0.00020, 95% CI: −0.00009, −0.00027). Data for nonoverweight 
prepregnancy BMI are shown in black; and overweight/obese 
prepregnancy BMI are shown in gray.
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(but  neither hormone alone) simply maintains initial rates of 
ob gene expression and leptin secretion, whereas in lean indi­
viduals, leptin expression and secretion actually increase in 
the adipose tissue (26). Moreover, changes in insulin response 
may have different physiological implications for obese 
women than for normal­weight women during pregnancy 
(8). We speculate that the observed differences in circulating 
 leptin levels may also be influenced by differences in leptin 
bioavailability or clearance, although little is known about 
these pathways.
These findings corroborate recent data suggesting that the 
regulation of metabolic pathways may be substantially differ­
ent in overweight and obese individuals compared to their 
normal­weight counterparts (4–6). Although few studies have 
investigated how such metabolic dysregulation may influ­
ence the physiological changes of pregnancy, one recent study 
demonstrated that obesity status early in pregnancy modified 
the association between insulin homeostasis and gestational 
weight gain (8). There have been no comparable studies docu­
menting how other obesity­related factors, such as adipokine 
profiles, may differ between overweight/obese and normal­
weight pregnant women. Our findings are among the first to 
describe the dynamic course of leptin levels from the earliest 
stages of pregnancy and emphasize the substantial differences 
in the trajectories between these groups.
Although our statistical analysis was somewhat limited by 
our relatively modest sample size, this work represents one of 
the largest prospective, longitudinal studies of leptin concen­
trations during pregnancy reported in the literature; similar 
studies are limited to one or two time points during gestation, 
or include far fewer women. In addition, we were able to obtain 
multiple measures of maternal serum leptin concentrations on 
each participant starting in early first trimester and at multiple 
time points across pregnancy. Few studies have used appropri­
ate longitudinal statistical methods to analyze such data. Our 
analytical approach used linear mixed models that accounted 
for the longitudinal data structure to describe gestational age–
dependent changes in leptin levels during pregnancy. As a 
result, we were able to map a detailed trajectory of leptin levels 
in a population­based cohort of pregnant women. This study 
design and analytical plan specifically enabled us to discern 
effects of maternal overweight/obesity on these trajectories.
Despite our sample size and multiple measures of our 
 covariates, we still lack statistical power for meaningful multi­
variable models to investigate the interrelationships among 
covariates. The effects of psychosocial, nutritional, and other 
metabolic variables on the relationship between maternal pre­
pregnancy BMI and leptin trajectory remain to be determined. 
However, we hypothesize that the effects of such distal obesity­
related factors may act through a set of proximal metabolic and 
physio logical factors, including adipokine pathways, that affect 
the course of pregnancy.
Our study design also inherently limits study participa­
tion to a group of women who present for early prenatal care 
and are able to attend multiple study visits. Women with­
out prenatal care or with late, interrupted, or sporadic care 
are less likely to have been included. As a result,  maternal 
 sociodemographic covariates show limited variation. 
Although our sample is homogeneous with regard to meas­
ures of socioeconomic  status and race, there is considerable 
variation in prepregnancy BMI, our exposure of interest. By 
focusing on this  population, many potential confounding 
factors, both measured and unmeasured, are accounted for 
by our sampling, allowing us to focus primarily on the effects 
of maternal overweight/obesity.
Many metabolic and physiological systems contribute to the 
“obese intrauterine environment.” The differences we observe in 
serum leptin profiles between overweight and nonoverweight 
women may represent one factor that contributes to this envi­
ronment. We speculate that fetal exposure to such differences 
in the obese intrauterine environment may “program” a set of 
physiological responses that predisposes offspring to metabolic 
and cardiovascular disease later in life (1–3). Our study is a 
first step toward understanding the effects of maternal  obesity 
on changes in maternal metabolic and physiological factors 
that influence the intrauterine environment and pregnancy 
outcomes. Such an understanding may have implications for 
the design of interventions to reduce  obesity­related preg­
nancy complications and adverse pregnancy  outcomes. If the 
consequences of maternal obesity result from lasting dysregu­
lation of metabolic homeostasis, then efforts to change health 
 behaviors and nutrition without correcting the underlying 
metabolic abnormalities may not be effective. As such, future 
studies are needed to evaluate how the pathogenic effects of 
obesity may be associated with metabolic dysregulation and 
disruption of the normal feedback systems that  maintain 
 metabolic  homeostasis during pregnancy.
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